Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (131-140 of 787) with videos related to

Pageof 79
Sort By:
Revue Medicale De Liege|April 7, 2017
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes]A J Scheen
Revue Medicale De Liege|April 8, 2017
A J Scheen
Diabetes & Metabolism|June 21, 2020
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?A J Scheen
Revue Medicale De Liege|November 23, 2006
[Increasing cost of insulin therapy in Belgium. From a critical analysis of the situation to a search for practical solutions]A J Scheen
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 12, 2000
Treatment of diabetes in patients with severe obesityA J Scheen
Revue Medicale De Liege|June 13, 2013
[How I treat ... with metformin a diabetic patient with moderate renal insufficiency]A J Scheen
Revue Medicale De Liege|June 18, 2016
[Taking into account both chronology and duration of events is crucial in the medical interview]A J Scheen
Revue Medicale De Liege|June 3, 2022
[Anti-inflammatory drugs : from old classical ones to biotherapies and JAK inhibitors]A J Scheen
Revue Medicale De Liege|December 7, 2010
[Suspension of the commercialization of sibutramine and rosiglitazone in Europe]A J Scheen
Revue Medicale De Liege|March 8, 2011
[Still further crisis...the scene in Belgium]A J Scheen
Pageof 79

Showing results (131-140 of 787) with videos related to

Sort By:
Pageof 79
Revue Medicale De Liege|April 7, 2017
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes]A J Scheen
Revue Medicale De Liege|April 8, 2017
A J Scheen
Diabetes & Metabolism|June 21, 2020
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?A J Scheen
Revue Medicale De Liege|November 23, 2006
[Increasing cost of insulin therapy in Belgium. From a critical analysis of the situation to a search for practical solutions]A J Scheen
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 12, 2000
Treatment of diabetes in patients with severe obesityA J Scheen
Revue Medicale De Liege|June 13, 2013
[How I treat ... with metformin a diabetic patient with moderate renal insufficiency]A J Scheen
Revue Medicale De Liege|June 18, 2016
[Taking into account both chronology and duration of events is crucial in the medical interview]A J Scheen
Revue Medicale De Liege|June 3, 2022
[Anti-inflammatory drugs : from old classical ones to biotherapies and JAK inhibitors]A J Scheen
Revue Medicale De Liege|December 7, 2010
[Suspension of the commercialization of sibutramine and rosiglitazone in Europe]A J Scheen
Revue Medicale De Liege|March 8, 2011
[Still further crisis...the scene in Belgium]A J Scheen
Pageof 79